|
Ahmedabad-based Intas Pharmaceuticals has cemented its position as a top-tier performer in the Indian Pharmaceutical Market (IPM), successfully maintaining the 6th rank for both the highly competitive month of September 2025 and the preceding Moving Annual Turnover (MAT) period.
The firm distinguished itself with commendable double-digit expansion in both monthly and annual measures, standing out as a consistent growth driver in an increasingly competitive sector. This stable high-level performance underscores a successful, targeted strategy in capturing and retaining market value across India's vast and diverse healthcare landscape.
A closer analysis of the single-month data for September 2025 reveals Intas Pharma's aggressive market activity. The company reported a robust monthly growth rate of 10.89 per cent, considerably surpassing the average monthly expansion and many of its immediate peers. This significant September surge translated into a gross sales value of Rs. 805.54 crore, securing a vital 3.75 per cent of the total monthly market share for the period.
The longer-term Moving Annual Turnover (MAT) figures powerfully validate this upward sales momentum, demonstrating enduring stability and expansion throughout the year. Intas concluded the MAT period ending September 2025 with an impressive total sales value exceeding Rs. 8,973 crore. Critically, the annualized growth rate stood firmly at 10.04 per cent, reinforcing the company's foundational strength within the broader IPM ecosystem.
A key indicator of superior market performance is the EVOL factor (Evolution Factor), which for Intas was registered at 102.09, signifying that its growth rate slightly outpaced the overall expansion of the market itself. Furthermore, achieving a sustained MAT market share of 3.70 per cent indicates that Intas is not just growing with the tide, but is successfully expanding its core footprint in proportion to the industry's overall size. This reflects effective commercial execution and a reliable demand for its product portfolio.
A deep dive into the geographical sales figures highlights the substantial contribution from various regions, particularly the dynamic northern markets. Intas strategically captured significant high-growth opportunities in this region, exemplified by an extraordinary 19 per cent growth in the high-volume Delhi market. Other northern states also delivered strong results, including an exceptional 17 per cent growth in Uttarakhand and a noteworthy 15 per cent expansion in the critical state of Rajasthan.
Beyond the North, Intas successfully maintained its competitive edge in the East while navigating challenges in the South. Key Eastern territories like West Bengal, including the metropolitan hub of Kolkata, continued to show solid double-digit expansion, registering 11 per cent growth in the state and 12 per cent growth in the city, respectively. In contrast, the Chennai market in the South presented a difficult terrain, with sales registering a -5 per cent decline in the region, suggesting a need for focused commercial interventions in a few select southern territories.
This overall market success and rising valuation are directly underpinned by key therapeutic products that are driving significant revenues and market adoption. High-performing brands like Neukine and Zoryl-M emerged as strong contributors to the MAT sales, with Neukine's value surging by 28 per cent and Zoryl-M seeing an 11 per cent increase. The impressive momentum generated by these brands positions Intas Pharma favourably to climb even higher in the rankings and sustain its double-digit growth trajectory in the coming fiscal periods.
|